Open AccessRemission With Venlafaxine Extended Release or Selective Serotonin Reuptake Inhibitors in Depressed Patients
Author(s) -
Michael E. Thase,
Philip T. Ninan,
Jeff Musgnung,
Madhukar H. Trivedi
Publication year - 2011
Publication title -
primary care companion to cns disorders/the primary care companion for cns disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.328
H-Index - 50
eISSN - 2155-7772
pISSN - 2155-7780
DOI - 10.4088/pcc.10m00979blu
Subject(s) - venlafaxine , paroxetine , citalopram , major depressive disorder , fluoxetine , sertraline , venlafaxine hydrochloride , reuptake inhibitor , serotonin reuptake inhibitor , medicine , hamilton rating scale for depression , repeated measures design , depression (economics) , psychology , psychiatry , antidepressant , serotonin , statistics , receptor , mathematics , macroeconomics , amygdala , hippocampus , economics
This randomized, open-label, rater-blinded, multicenter study compared treatment outcomes with the serotonin-norepinephrine reuptake inhibitor (SNRI) venlafaxine extended release (ER) with selective serotonin reuptake inhibitors (SSRIs) in primary care patients with major depressive disorder.